* Strong potential for margin improvements * Short term priorities presented * Favourable sales mix ...
Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farm...
* Strong early data point with 25% conversion rate for Doro in D2C * .
* CFO and new CEO gave a general presentation * Some positive market signs, mainly in public and tel...
Siili lowered its guidance for EBITA; the new guidance range mid-point stands c.
Redeye comments on decision by the VGR Regional Board regarding Millennium and the modular alternati...
ChargePanels månatliga omsättning har ökat med 18,3 respektive 34,4 procent under september och okto...
Redeye provides a summary of Sdiptech’s CMD. The event presented slightly updated financial targets,...
Alligator Bioscience has secured additional subscription and top guarantee commitments for its SEK12...
SyntheticMR redovisade ett svagt tredje kvartal där omsättningen sjönk med 7 procent och resultatet ...
* Rail and Kvalitetsbygg sold, while we see... * ..
Redeye retains its positive take on Formpipe following the finalisation of the Public divestment and...
* Public divestment completed (EV SEK 850m)... * ..
Redeye provides an update following Mindark’s Q3 2025 report.
Will lower financial expenses by SEK 2m per year We estimate ND/EBITDA of ~1.
Mindark redovisade ökad nettoomsättning och minskad EBIT i det tredje kvartalet.
Redeye provides an update on Saniona. In Q3, Saniona expectedly received the USD42.
Redeye comments on MindArk’s Q3 results, which showed figures in line with estimates, apart from sli...
* An organic decline of 3% in Q3 * We cut sales estimates by 4-2% for '26e-'27e * Positioned for a m...
Redeye provides a summary of Paxman’s CMD. The event offered no material surprises and introduced li...
